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animals could still be cross-presented to
CD8+ T cells (Bertholet et al., 2006). Be-
cause TAP is required for the transloca-
tion of peptides from the cytoplasm to
the ER lumen, these results suggest that
direct loading of exogenous peptides on
MHC class I molecules occurred directly
in the phagosome lumen. The efficiency
of this process appeared, however, to
be limited. Hence, Irgm3 would enhance
cross-presentation by improving the mo-
lecular mechanisms connecting the early
step of protein processing in phagosomes
with the loading of peptides onMHC class
I molecules. A surprising result revealed
by Bougne`res et al. (2009) is that although
Irgm3+ LBs were often observed in the
close vicinity of phagosomes, no notice-
able accumulation of Irgm3 was observed
on these organelles by immunofluores-
cence. This observation suggests that
Irgm3 has an indirect effect on the
phagosomal cross-presentation machin-
ery, possibly through LBs. We have
shown recently, by using quantitative pro-
teomics analyses, that the relative amount
of several members of the p47 family,
including Irgm3, increased markedly on
phagosomes isolated from macrophages
treated with IFN-g, compared to control
cells (Trost et al., 2009). These results
would rather argue that Irgm3 is directly
involved in the ability of phagosomes to
participate in cross-presentation. Another
effect of IFN-g highlighted in recent
studies is the ability of this cytokine to
modulate the conditions encountered in
the phagosome lumen to promote a
limited hydrolysis of proteins favoring the
generation of peptides suited for loading
on MHC molecules (Yates et al., 2007;
Trost et al., 2009). Interestingly, Boug-
ne`res et al. (2009) indicate that Irgm3
inhibits phagosome maturation, without
altering the rate of phagocytosis, a pro-
cess that should, in principle, limit the
rapid proteolysis of peptides and favor
antigen presentation.
More studies will highlight the relative
contribution of Irgm3 and LBs to cross-
presentation, as well as the role of this
protein in the interaction between phago-
somes and LBs. A thorough characteriza-
tion of the molecular organization and
biogenesis of LBs will also provide key
elements to understanding the molecular
nature of the interaction occurring be-
tween LBs and the other organelles in-
volved in cross-presentation, including
phagosomes and autophagosomes. Con-
sidering the fact that LBs display a mono-
layermembrane, onemight argue that this
type of interaction might influence the
lipid organization of the outer membrane
of these organelles and/or the associ-
ation of cytoplasmic anchored proteins
like Irgm3.
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The functions of T lymphocytes are regulated by transcription factors controlling gene expression. Three
studies in this issue of Immunity (Kallies et al., 2009; Rutishauser et al., 2009; Shin et al., 2009) indicate
that the transcriptional repressor Blimp-1 promotes the development of short-lived effector cells and regu-
lates clonal exhaustion.The B cell transcriptional repressor
Blimp-1 (B lymphocyte-induced matura-
tion protein-1), encoded by the Prdm1
gene locus, is known as a decision maker
in the fate of B cells by regulating genes
promoting B cell terminal differentiation
into plasma cells but not into memory B
cells (Shaffer et al., 2002; Shapiro-Shelef178 Immunity 31, August 21, 2009 ª2009 Elsetal., 2003).More recent studies, including
three in this issue of Immunity, indicate
that Blimp-1may provide similar functions
for CD8+ T cells, by promoting the terminal
differentiation of most into short-lived
cytotoxic T lymphocytes (CTLs) rather
than long-lived central memory (CM)
T cells (Kallies et al., 2009; Rutishauserevier Inc.et al., 2009; Shin et al., 2009). Although
originally defined in B cells, Blimp-1 is
important for the development of multiple
lineages during embryogenesis and is
also known to promote terminal differenti-
ation of skin keratinocytes (John and Gar-
rett-Sinha, 2009). Mice with T cell-specific
deletions in Blimp-1 develop severe
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PreviewsFigure 1. Blimp-1 and the Fates of T Cells during Viral Infections
This figure portrays fates of CD8 T cells that either do or do not express Blimp-1 during a viral infection.
Naive T cells sensing antigen will secrete IL-2 and other cytokines and ultimately enter different differen-
tiation pathways. IL-2 can stimulate expression of Blimp-1, which, in turn, will shut down IL-2 expression.
Blimp-1+ cells can migrate into peripheral tissues, become short-lived effector cells under conditions of
low antigen load, and become clonally exhausted under conditions of high antigen load. Some survive
longer term as effector memory cells. Cells lacking Blimp-1 migrate relatively poorly into the periphery,
produce IL-2, and are most of the memory cell precursors, evolving to become central memory cells.immunopathology, indicating a require-
ment for Blimp-1 in normal T cell homeo-
stasis (Kallies et al., 2006). Blimp-1 is
induced in T cells by IL-2 and other cyto-
kines, but its expression represses Il2
gene transcription (Martins et al., 2008).
Thus, it can serve in a negative feedback
process, altering T cell gene expression.
How then, does the activity of Blimp-1
act on the T cell response to viral infec-
tion? Viruses are notoriously strong stim-
ulators of CD8+ CTLs, which can lyse
virus-infected targets and control viral
replication by secreting antiviral cyto-
kines such as interferon-g (IFN-g). Virus-
specific T cells undergo a programmed
expansion and differentiation into effector
cells and thereafter contract in numbers
because of apoptosis, leaving a smaller
but stable subpopulation of memory
T cells that can vigorously respond to
reinfection at a later date (Harty and
Badovinac, 2008). T cells activated during
the acute infection can express different
antigens that predict their fate. For
example, mouse memory CD8+ T cells
are more likely to be derived from T cells
expressing high amounts of the IL-7receptor (CD127) and low amounts of
the natural killer cell receptor KLRG1,
whereas short-lived effector cells are
more likely to be CD127lo, KLRG1hi
(Parish and Kaech, 2009). Overwhelming
viral loads, however, can drive T cells
either into a clonal deletion by apoptosis
or into a functional exhaustion associated
with the expression of T cell inhibitory re-
ceptors, such as PD-1, LAG-3, 2B4, and
CD160 (Blackburn et al., 2009). These
new studies indicate that Blimp-1 is an
important regulator of all of these fates.
Rutishauser et al. (2009) examined the
role of Blimp-1 during the CD8+ T cell re-
sponse of mice acutely infected with lym-
phocytic choriomeningitis virus (LCMV),
strain Armstrong. Using mice in which
the gene for yellow fluorescent protein
(yfp) was under the control of Blimp-1
promoter elements, they found high ex-
pression of Blimp-1 in most cells during
the acute response and lower expression
in memory cells after resolution of infec-
tion. Blimp-1 mRNA, protein, and YFP
reporter expression were high in the
CD127loKLRG1hi population of short-lived
effector cells and low in the memoryImmunity 3precursor CD127hiKLRG1lo cells. In the
memory state, Blimp-1 expression re-
mained elevated for some time in effector
memory (EM) phenotype cells (CD127lo
KLRG1hiCD27loCD62Llo) but low in the
more frequent CM phenotype cells
(CD127hiKLRG1loCD27hiCD62Lhi), which
are considered highly proliferative on
antigenic rechallenge. This suggests
that Blimp1 expression distinguishes the
effector cell lineage from the CM lineage.
These authors crossed mice carrying
the loxP-flanked Pdrm1 gene (encoding
Blimp-1) with mice carrying cre-recombi-
nase under control of the Granzyme B
promoter, such that T cells would delete
the Prdm1 gene when they became acti-
vated during infection. These Prdm1/
mice had reduced frequencies of
short-lived effector cells and a reduced
contraction phase, coupled with en-
hanced overall survival of virus-specific
CD8+ T cells.
During the acute LCMV infection,
Blimp-1 deficiency yielded populations
of CD8+ T cells that could produce rela-
tively normal amounts of IFN-g and TNF,
but they produced less Granzyme B,
which is involved in cytotoxicity, and
much more IL-2 than wild-type (WT) cells.
The relatively low IL-2 in Blimp-1+ cells
and high amounts in Blimp-1 cells is
consistent with Blimp-1 being a transcrip-
tional repressor of the Il2 gene (Martins
et al., 2008). These same functional prop-
erties of Prdm1/ T cells were also noted
in the studies of Kallies et al. (2009) and
Shin et al. (2009), and all three groups
correlated Blimp-1 expression with short-
lived effector cells and the absence of
Blimp-1 expression with the generation
of CM cells (Figure 1).
Shin et al. (2009) compared Blimp1
expression in T cells from mice under-
going acute LCMV-strain Armstrong in-
fection to those from mice undergoing a
persistent infection established by high-
dose inoculation with the highly dissemi-
nating clone 13 variant of LCMV. In both
infections, Blimp-1 mRNA or Blimp-1-
YFP was elevated initially, but Blimp-1
expression then became especially ele-
vated during the persistent infection.
Blimp-1 was most highly expressed in
T cells specific for the LCMV-encoded
NP396 peptide, and these are usually
the first T cells to exhaust or undergo
apoptosis during persistent LCMV infec-
tion. Cells undergoing clonal exhaustion1, August 21, 2009 ª2009 Elsevier Inc. 179
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amounts of PD-1, and the PD-1hi cells ex-
pressed 2- to 3-fold more Blimp-1 mRNA
than did a subset expressing lower
amounts of PD-1. In general, expression
of Blimp1-YFP was highest in CD8+
T cells expressing T cell-exhaustion-asso-
ciated inhibitory receptors, such as PD-1,
Lag-3, 2B4, and CD160. LCMV-specific
T cells from persistently infected Blimp-
1-deficient mice expressed low amounts
of inhibitory receptors, resisted clonal
exhaustion, and were at higher frequen-
cies than those in infected WT mice, and
many expressed high amounts of CD127
and CD62L, consistent with a CM pheno-
type. Decreased inhibitory receptor ex-
pression on T cells in the absence of
Blimp-1might predict thatPrdm1/mice
would clear persistent LCMV quickly, but
this did not happen. Blimp-1 was also
needed for effector cell function, and
Prdm1/ T cells had reduced cytotoxicity
against viral-peptide-coated targets.
However, ‘‘haploinsufficient’’ mice, con-
structed to have only one copy of the
Prdm1 gene, had reduced expression
of Blimp-1 and cleared LCMV better,
presumably because this intermediate
amount of Blimp-1 allowed for effector
cell function without upregulating inhibi-
tory receptors (Shin et al., 2009).
Kallies et al. (2009) made chimeric mice
with an immune system derived from fetal
liver cells of mice whose Prdm1 gene was
inactivated by a green fluorescent protein
knock-in (Prdm1gfp) and found that those
mice suffered severely from an influenza
A virus (IAV) infection that was tolerated
in control mice. Bone marrow chimeric
mice were next made with a combination
of Prdm1gfp/gfp (Blimp-1-deficient) and
Prdm1+/+ (WT control), and the presence
of the WT cells allowed for enhanced
resistance to IAV and the opportunity to
compare the responses of Prdm1gfp/gfp
to WT cells under similar conditions of
viral load. These Blimp-1-deficient T cells
in IAV-challenged chimeric mice lacked180 Immunity 31, August 21, 2009 ª2009 Elsthe short-lived effector phenotype and
highly expressed the memory cell tran-
scription factor eomesodermin and the
memory cell-associated transcriptional
repressor Bcl-6, also detected in the
molecular screens of Rutishauser et al.
(2009). After resolution of infection, a
high proportion of Blimp-1-deficient cells
were CD127hiCD62Lhi, consistent with
a CM phenotype. Thus, all three studies
indicate that Blimp-1 expression is asso-
ciated with effector cells and its absence
is associated with long-lasting CM cells
or their precursors.
Kallies et al. (2009) also detected a
potentially important cell migration phe-
notype. After a primary IAV infection of
chimeric mice, the Blimp-1-deficient
CD8+ T cell frequency was relatively nor-
mal in the spleen but markedly reduced
in the lungs, in comparison to WT cells.
On IAV challenge of mice previously
immunized with another IAV strain, the
Prdm1gfp/gfp T cells were elevated in the
spleen but again low in the lung, com-
pared to WT controls. These experiments
suggested that Blimp-1 was needed for
trafficking into the lung, and indeed, in
the Blimp-1-deficient cells the expression
of the lung-homing chemokine receptor
CCR5 was reduced, and expression of
CCR7, important for recruitment into the
spleen and lymph nodes, was elevated.
Together, these reports indicate that
Blimp-1 promotes the generation of
short-lived effector T cells, the generation
of clonally exhausted T cells, and the
migration of T cells out of the spleen and
lymph nodes and into peripheral tissues.
Blimp-1 expression does permit the gen-
eration of some longer-lived EM cells,
but its absence allows for the generation
of long-term CM cells, which are thought
to have higher proliferative potential on
secondary challenge. Blimp-1 is a tran-
scriptional repressor of IL-2 (Martins,
et al., 2008), and the generation of poly-
functional T cells having the ability to
make IL-2 has been correlated with moreevier Inc.protective antiviral responses in vaccine
studies (Seder et al., 2008). What remains
unclear is why some T cells express
Blimp-1 and others do not, but cytokines
can stimulate its expression. The contrac-
tion phase of T cell responses is less
dramatic when T cells are stimulated in
low inflammatory environments (Harty and
Badovinac, 2008). Perhaps high amounts
of inflammatory cytokines promote the
expression of Blimp-1 and the generation
of short-lived effector cells, whose expan-
sion and then loss would cause a greater
contraction.
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